biomarkers

An invasion front gene expression signature for higher-risk patient selection in stage IIA MSS colon cancer
Stage II colon cancer (CC) encompasses a heterogeneous group of patients with diverse survival experiences: 87% to 58% 5-year relative …
PDF Cite Project DOI
An invasion front gene expression signature for higher-risk patient selection in stage IIA MSS colon cancer
An explorative analysis of ABCG2/TOP-1 mRNA expression as a biomarker test for FOLFIRI treatment in stage III colon cancer patients: results from retrospective analyses of the PETACC-3 trial
Biomarker-guided treatment for patients with colon cancer is needed. We tested ABCG2 and topoisomerase 1 (TOP1) mRNA expression as …
PDF Cite Project DOI
An explorative analysis of ABCG2/TOP-1 mRNA expression as a biomarker test for FOLFIRI treatment in stage III colon cancer patients: results from retrospective analyses of the PETACC-3 trial
ONCOBIOME: Gut OncoMicrobiome Signatures associated with cancer incidence, prognosis and prediction of treatment response
Exploiting the gut microbiome for cancer diagnosis and treatment
ONCOBIOME: Gut OncoMicrobiome Signatures associated with cancer incidence, prognosis and prediction of treatment response
Clinical implications of intra-tumour heterogeneity in colon cancer
Region-based biomarkers.
Clinical implications of intra-tumour heterogeneity in colon cancer
A Phase Ia/b study of MEK1/2 inhibitor PD-0325901 or MEK-162 with cMET inhibitor PF-02341066 in RASMT and RASWT (with aberrant c-MET) Colorectal Cancer Patients.
Clinical trial for cMET inhibitor
A Phase Ia/b study of MEK1/2 inhibitor PD-0325901 or MEK-162 with cMET inhibitor PF-02341066 in RASMT and RASWT (with aberrant c-MET) Colorectal Cancer Patients.